Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)

Trial Profile

Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Adverse reactions
  • Sponsors Ablynx
  • Most Recent Events

    • 29 Nov 2017 This trial has been completed in Germany (end date:2017-05-17).
    • 09 Nov 2017 Planned End Date changed from 1 Jul 2020 to 1 Oct 2020.
    • 09 Nov 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top